JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Oral Seltorexant as an add-on Medication to an Antidepressant on On-road Driving Performance in Participants With Major Depressive Disorder

Phase 1

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: Seltorexant Dose 1
Drug: Seltorexant Dose 2
Drug: Placebo
Drug: Zopiclone

First Posted Date: 2020-06-30

Last Posted Date: 2023-03-31

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 63

Registration Number: NCT04451187

Locations: 🇧🇪
Anima, Alken, Belgium
🇩🇪
Universitaetsklinikum der RWTH Aachen, Aachen, Germany

A Study of JNJ-70033093 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-70033093

First Posted Date: 2020-06-26

Last Posted Date: 2020-12-14

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 24

Registration Number: NCT04448964

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

Phase 2

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: JNJ-73763989
Drug: PegIFN-alpha-2a
Drug: Tenofovir disoproxil
Drug: Tenofovir alafenamide
Drug: JNJ-56136379

First Posted Date: 2020-06-19

Last Posted Date: 2024-12-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 54

Registration Number: NCT04439539

Locations: 🇬🇧
Kings College Hospital, London, United Kingdom
🇬🇧
Grahame Hayton Unit, London, United Kingdom
🇺🇸
Ruane Clinical Research Group Inc, Los Angeles, California, United States

and more 44 locations

A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lazertinib
Drug: Rifampin
Drug: Itraconazole

First Posted Date: 2020-06-01

Last Posted Date: 2021-03-01

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 32

Registration Number: NCT04410094

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Study of (14C)-JNJ-73841937 (Lazertinib) in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 14C-lazertinib

First Posted Date: 2020-06-01

Last Posted Date: 2021-03-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 8

Registration Number: NCT04410081

Locations: 🇳🇱
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

Phase 1

Active, not recruiting

Conditions: Neoplasms

Interventions: Drug: JNJ-70218902

First Posted Date: 2020-05-21

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 82

Registration Number: NCT04397276

Locations: 🇨🇦
BC Cancer Agency - Vancouver BC, Vancouver, British Columbia, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇮🇱
Rambam Medical Center, Haifa, Israel

and more 4 locations

A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants

Completed

Conditions: Uterine Hemorrhage

Interventions: Drug: Direct oral anticoagulant (DOACs)
Drug: Warfarin

First Posted Date: 2020-05-19

Last Posted Date: 2020-06-11

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 961985

Registration Number: NCT04394234

Locations: 🇺🇸
Janssen R&D, Titusville, New Jersey, United States

A Study of Guselkumab in Participants With Active Lupus Nephritis

Phase 2

Terminated

Conditions: Lupus Nephritis

Interventions: Drug: Guselkumab Dose 1
Drug: Placebo
Drug: Guselkumab Dose 2
Drug: Standard-of-care treatment

First Posted Date: 2020-05-06

Last Posted Date: 2024-04-16

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 33

Registration Number: NCT04376827

Locations: 🇦🇷
Centro de Investigaciones Medicas Tucuman, San Miguel De Tucuman, Argentina
🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
🇺🇸
UC San Diego, La Jolla, California, United States

and more 57 locations

A Study of JNJ-53718678 in Participants With Hepatic Impairment

Phase 1

Terminated

Conditions: Hepatic Impairment

Interventions: Drug: JNJ-53718678

First Posted Date: 2020-04-02

Last Posted Date: 2022-06-13

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 25

Registration Number: NCT04332523

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
The Texas Liver Institute, San Antonio, Texas, United States

Long-term Follow-up Gene Therapy Study for RPGR- XLRP

Active, not recruiting

Conditions: X-Linked Retinitis Pigmentosa

Interventions: Biological: AAV5-hRKp.RPGR

First Posted Date: 2020-03-18

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 42

Registration Number: NCT04312672

Locations: 🇺🇸
Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇬🇧
Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy